Physician profile
Michael G Schafer
NPI 1831115369
$2,307.83
in general payments reported to CMS, 2019-2025
23 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $502 · 2021: $334 · 2022: $265 · 2023: $323 · 2024: $147 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.23 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.87 | 2021-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $355.16 | 2019-2025 | Trelegy Ellipta |
| Allergan, INC. | $231.73 | 2019-2020 | |
| Novo Nordisk INC | $189.69 | 2019-2024 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.18 | 2019-2021 | |
| Pfizer INC. | $109.54 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $97.95 | 2022 | |
| Amgen INC. | $87.39 | 2020-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $72.87 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.53 | 2023-2025 | |
| Abbott Laboratories | $63.30 | 2019-2023 | Freestyle Libre 3 |
| Medtronic, INC. | $48.49 | 2021-2022 | |
| Dexcom, INC. | $46.88 | 2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $46.04 | 2020 | |
| Shire North American Group INC | $45.97 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.99 | 2019-2021 | |
| Lilly USA, LLC | $40.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $28.18 | 2020 | |
| Sunovion Pharmaceuticals INC. | $24.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.16 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.40 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.73 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schafer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.